---
schema_version: "secwatch.filing_event.v1"
accession: "0001140361-24-044703"
form_type: "8-K"
ticker: "INSM"
cik: "0001104506"
company_name: "INSMED Inc"
filed_at: "2024-10-31T23:59:59+00:00"
generated_at: "2026-05-30T07:15:05.658517+00:00"
event_type: "earnings"
sentiment: "neutral"
materiality_score: 0.75
calibrated_materiality_score: 0.75
confidence: "high"
source: SEC EDGAR
---

# Insmed Q3 ARIKAYCE revenue $93.4M (+18% YoY); net loss $1.27/sh; adds $150M loan

## Summary
- ARIKAYCE global revenue $93.4M in Q3 2024, up 18% YoY; US $66.9M, Japan $21.0M, Europe/RoW $5.6M.
- Net loss $220.5M ($1.27/sh) vs $158.9M ($1.11/sh) in Q3 2023; operating loss $213.4M.
- NDA for brensocatib in bronchiectasis on track for Q4 2024; potential US launch mid-2025.
- Amended Pharmakon loan adds $150M tranche at 9.60% fixed, maturity extends to Sept 2029.
- Ended Q3 with ~$1.5B cash; redeemed $225M convertible notes; raised $371M net via ATM.

## SEC filing metadata
- accession: 0001140361-24-044703
- form_type: 8-K
- ticker: INSM
- cik: 0001104506
- company_name: INSMED Inc
- filed_at: 2024-10-31T23:59:59+00:00
- event_type: earnings
- sentiment: neutral
- materiality_score: 0.75
- calibrated_materiality_score: 0.75
- confidence: high
- sec_items: 1.01, 2.02, 2.03, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1104506/000114036124044703/0001140361-24-044703-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1104506/000114036124044703/ef20037942_8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001140361-24-044703
- JSON: https://secwatch.observer/filing/0001140361-24-044703.json
- Plain text: https://secwatch.observer/filing/0001140361-24-044703.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.